JNS: US-based pharmaceutical giant Johnson and Johnson’s (J&J) single-dose Covid-19 vaccine gets Emergency Use Approval (EUA) from the government of India in a bid to expand India’s vaccine basket,
J&J vaccine has been authorised by WHO and is available in most nations on an emergency basis.
J&J becomes the fifth vaccine to get Emergency Use Approval in India by the government of India. The other four vaccines include Bharat Biotech’s Covaxin, Serum Institute of India’s Covishield, SputnikV by Gamaleya Research Institute and Moderna.
Minister of Health and Family Welfare, Mansuk Mandaviya tweeted, “India expands its vaccine basket! Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines.”
J&J has joined hands with Biological E Limited, an Indian biotechnology and biopharmaceutical company based in Hyderabad, for the supplying and manufacturing of the vaccines.
The international pharma company earlier in a statement issued on 5th August 2021 has stated that Biological E will be an important part of Johnson and Johnson’s global supply chain network, helping to supply its COVID-19 vaccine, named Janssen through extensive collaborations and partnerships with governments, health authorities and organisations such as Gavi and the COVAX Facility.
